| __timestamp | Mesoblast Limited | Viridian Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 54170000 | 7751000 |
| Thursday, January 1, 2015 | 65378000 | 10251000 |
| Friday, January 1, 2016 | 52263000 | 9575000 |
| Sunday, January 1, 2017 | 35072000 | 10912000 |
| Monday, January 1, 2018 | 27415000 | 11049000 |
| Tuesday, January 1, 2019 | 36983000 | 11646000 |
| Wednesday, January 1, 2020 | 50918000 | 13265000 |
| Friday, January 1, 2021 | 63586000 | 25805000 |
| Saturday, January 1, 2022 | 57967000 | 35182000 |
| Sunday, January 1, 2023 | 53107000 | 94999000 |
| Monday, January 1, 2024 | 23626000 |
Unleashing the power of data
In the ever-evolving landscape of biotechnology, understanding financial health is crucial. This chart offers a glimpse into the Selling, General, and Administrative (SG&A) expenses of two prominent players: Mesoblast Limited and Viridian Therapeutics, Inc., from 2014 to 2023.
Mesoblast Limited, an Australian regenerative medicine company, has seen its SG&A expenses fluctuate, peaking in 2015 and 2021. Notably, their expenses in 2023 were approximately 56% lower than their 2015 peak. In contrast, Viridian Therapeutics, Inc., a U.S.-based biotech firm, experienced a dramatic rise in SG&A costs, with a staggering 1,125% increase from 2014 to 2023.
This data highlights the contrasting financial strategies and growth trajectories of these companies, offering valuable insights for investors and industry analysts. Missing data for 2024 suggests ongoing developments worth monitoring.
SG&A Efficiency Analysis: Comparing argenx SE and Mesoblast Limited
Selling, General, and Administrative Costs: Teva Pharmaceutical Industries Limited vs Mesoblast Limited
Neurocrine Biosciences, Inc. and Mesoblast Limited: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of Grifols, S.A. and Mesoblast Limited
SG&A Efficiency Analysis: Comparing Ultragenyx Pharmaceutical Inc. and Viridian Therapeutics, Inc.
CRISPR Therapeutics AG vs Mesoblast Limited: SG&A Expense Trends
Breaking Down SG&A Expenses: Veracyte, Inc. vs Mesoblast Limited
Breaking Down SG&A Expenses: Amicus Therapeutics, Inc. vs Mesoblast Limited
Protagonist Therapeutics, Inc. or Viridian Therapeutics, Inc.: Who Manages SG&A Costs Better?
SG&A Efficiency Analysis: Comparing Mesoblast Limited and MannKind Corporation
Mesoblast Limited or Iovance Biotherapeutics, Inc.: Who Manages SG&A Costs Better?
Mesoblast Limited and Wave Life Sciences Ltd.: SG&A Spending Patterns Compared